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Background: Non-HLA antibodies (Abs) targeting vascular receptors are considered to have an inﬂuence on
renal transplant injury. Anti-endothelin-1 type A receptor (anti-ETAR) antibodies were associated with cellular
and antibody-mediated rejection and early onset of vasculopathy in heart transplant patients but their role in
renal transplantation remains unclear. The aim of our study was to assess the incidence and importance of
anti-ETAR antibodies and their impact on renal transplant during the ﬁrst year observation.
Methods: We evaluated the presence of anti-ETAR antibodies in 116 consecutive renal transplant recipients in
pre- and post-transplant screening (before and in 1st, 3rd, 6th, 12th month after transplantation). Additionally,
we assessed the presence of anti-HLA antibodies. Anti-ETAR antibodies were assayed by ELISA. The diagnosis of
acute rejection was based on the Banff criteria.
Results: Anti-ETAR antibodies were observed in 55 (47.4%) of the analyzed recipients before transplantation. The
function of renal transplant was signiﬁcantly worse in the anti-ETAR(+) group compared to the anti-ETAR(−)
group during the ﬁrst post-transplant year. One month after transplantation the serum creatinine in anti-ETAR
(+) patients (pts) was 1.86 ± 0.8 mg/dl and 1.51 ± 0.5 in anti-ETAR(−) pts (p = 0.009). Twelve months
after transplantation the difference between the groups was still observed 1.70 ± 0.7 vs. 1.40 ± 0.4 (p = 0.04).
Biopsy proven acute rejection was recognized in 8/55 (14.5%) in ETAR(+) and 9/61 (14.8%) in ETAR(−) patients
but caseswithmild to severe intimal arteritis (v1–v3)weremore often observed in patients with the presence of
anti-ETAR Abs 4/55 (7.2%) comparing with 1/61 (1.6%) in anti-ETAR(−) patients. The anti-ETAR antibody levels
varied at different measurement intervals during the one-year follow-up.
Conclusions: The presence of anti-ETAR antibodies is associated with a worse renal transplant function during
the ﬁrst 12 months after transplantation. Including anti-ETAR antibodies in the diagnostics of renal transplant
recipient immune status should be considered to provide comprehensive assessment of humoral alloimmunity.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
There is accepted evidence for an important role of anti-HLA antibod-
ies (Abs) in acute and chronic rejection of renal transplant [1–7]. Humoral
response to non-HLA antigens is primarily directed to antigens expressed
on endothelial cells. The understanding of frequency and clinical impor-
tance of non-HLA antibodies production is incomplete [8]. The lack ofersity Grant Pbmn 102.
48 71 733 25 09.
. Open access under CC BY license.knowledge is connectedwith the identity of non-HLA targets and validat-
ed diagnostic screening assays for non-HLA antibodies detection [1]. En-
dothelial cells of vessels may be the primary target for antibodies [9]. It
has been mentioned that antigenic targets — two G-protein coupled
receptors: angiotensin II type 1 receptor and endothelin type A receptor
may have an important clinical signiﬁcance in transplantation [10].
Dragun et al. described the role of anti-angiotensin II type 1 receptor
antibodies (anti-AT1R Abs) in renal transplant damage [11,12]. We
have noticed the importance of non-HLA antibodies long time
after transplantation [13]. Elevated levels of anti-AT1R Abs and anti-
endothelin-1 type A receptor antibodies (anti-ETAR Abs) were
observed as associated with cellular and humoral rejection and early
onset of microvasculopathy after heart transplantation [14]. We
decided to verify the activity and incidence of anti-ETAR Abs in renal
transplant recipients early after transplantation.
Table 2
Initial immunosuppression.
Anti-ETAR(+)
n = 55
Anti-ETAR(−)
n = 61
p-Value
TAC-MMF/MPA + P 38 40 NS
CsA-MMF/MPA + P 17 21 NS
Simulect + TAC-MMF/MPA + P 3 5 NS
Simulect + CsA-MMF/MPA + P 1 0 NS
TAC—tacrolimus, MMF—mycophenolate mofetil, MPA—mycophenolic acid, P—prednizon,
CsA—cyclosporin.
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nated from endothelium. It was isolated from culture media of vascular
endothelial cells (EC) [15]. There are three distinct ET isopeptides
assayed — ET-1, ET-2 and ET-3 [16]. Because of a polymorphic nature
of some of non-HLA antigens theway of sensitizationmay be analogous
to that those of anti-HLA antibodies. Another other possibility is con-
nected with injury. Under physiologic conditions antigenic determi-
nants from targets for non-HLA antibodies are protected but become
accessible after injury [17]. Liberation and presentation of non-HLA
antigens at that time may induce an autoimmune response. Non-HLA
antibodies may also occur secondary to immune activation or in con-
nection with acute rejection [18]. Anti-ETAR Abs may also alone induce
endothelial activation stimulating proinﬂammatory, proproliferative,
and proﬁbrotic response [19].
The aim of our study was to assess the incidence and importance of
anti-ETAR antibodies and their impact on renal transplant during the
ﬁrst year observation.2. Methods
We prospectively evaluated the presence of anti-ETAR antibodies in
116 consecutive renal transplant recipients in pre- and post-transplant
screening (before and in 1st, 3rd, 6th, 12th month after transplanta-
tion). Additionally, we assessed the presence of anti-HLA antibodies.
Anti-ETAR antibodies were assayed by ELISA (CellTrend). The presence
of Anti-HLA antibodies was tested by the ﬂow-PRA method (One
Lambda). The diagnosis of acute rejection was based on the Banff
criteria. Patients' characteristics were presented in Table 1. The immu-
nosuppression consisted of: tacrolimus or cyclosporine, mycophenolate
mofetil, steroids and occasionally basiliximab (Table 2). In case of acute
rejection, the recipients received steroids. Patients' sera for the determi-
nation of antibody concentrations were obtained along the routine
examinations. Venous blood was drawn into sterile 10 mL serum
separator tubes. Samples were centrifuged at 1000 ×g for 15 min,
serum was collected and stored at (−80 °C) until the day of measure-
ment. The concentration of anti-ETAR IgG antibody in serum was mea-
sured by enzyme-linked immunosorbent assay using commerciallyTable 1
Patient population characteristics (n = 116).
Anti-ETAR(+)
n = 55
Anti-ETAR(−)
n = 61
p-Value
Recipients age (years) 44.6 ± 15 49.1 ± 14 NS
Male gender, n (%) 39 (70.1%) 34 (55.7%) NS
Time on dialysis before
transplantation (days)
1076 ± 1184 1217 ± 972 NS
First transplant 48 56 NS
Second/third transplant 6/1 5/0 NS
No of HLA mismatches 3.4 ± 1.4 3.5 ± 1.1 NS
No of presensitized patients 22/55 23/61 NS
PRA b10% 12 10 NS
PRA 10–50% 8 12 NS
PRA N50% 2 1 NS
Cold ischemia time (hours) 21.0 ± 8.2 21.4 ± 10.5 NS
Donor gender (%)
Female 39 39.1 NS
Male 61 60.9 NS
Donor age (years) 47.0 ± 15.0 45.2 ± 16.4 NS
Delayed graft function (days) 7.1 ± 5.4 6.4 ± 7.6 NS
Cause of chronic renal failure:
Chronic glomerulonephritis 17 16 NS
Diabetic nephropathy 4 5 NS
Hypertonic nephropathy 5 7 NS
Polycystic kidney disease 11 9 NS
Pyelonephritis 8 6 NS
Others 10 18 NS
HLA—human leukocyte antigen, PRA—panel reactive antibodies.available kits according to the manufacturer's instruction (CellTrend,
Luckenwalde, Germany). The samples were assayed on endothelin-
receptor A pre-coated microtiter plate. Standards and diluted 1:100
sampleswere added into thewells, and incubated for 2 h at the temper-
ature of 2–8 °C. After washing steps, anti-ETAR antibody was detected
with POD labeled anti-human IgG antibody (1:100) followed by color
development with TMB substrate solution measured at 450 nm, with
the correction wavelength set at 630 nm. Optical densities were then
converted into concentration through standard curve. The positive de-
tection range of the testwas≥2.5 U/mL and thenegative one amounted
to b2.5 U/mL.
There was no statistically signiﬁcant difference considering recipi-
ents' and donors' age or gender, cold ischemia time, the number of
HLA mismatches, the number of presensitized patients, immunosup-
pressive regiment or patients with the presence of anti-HLA antibodies
between the groups. The ethical commission of the Wroclaw Medical
University approved all study protocols and the informed consent was
obtained from all the patients.
2.1. Statistics
Statistica version 10 was used for statistical analysis. Continuous
data were presented as the mean ± SEM. The comparison between
the groups was performed using a Student t-test and the Mann–
Whitney U test for metric variables, while the chi-square test was
used to identify a connection between acute rejection and the presence
of antibodies. Univariate and multivariate logistic regression analyses
were performed to evaluate the association of chronic rejection risk
factors with anti-ETAR antibodies. The Fisher test was performed to as-
sess the inﬂuence of anti-ETAR antibodies level on arteritis and chronic
vasculopathy in the performed renal biopsies. The Spearman correlation
was also performed to choose the anti-ETAR level.
p value below 0.05 was considered signiﬁcant.
3. Results
Anti-ETAR antibodies were observed in 55 (47.4%) of the analyzed recipients
before transplantation. The patients were divided into two groups: anti-ETAR positive
(n = 55) and anti-ETAR negative (n = 61).0
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Fig. 1. Renal transplant function (serum creatinine) during one year after transplantation.
Table 3
Biopsy proven acute rejection, stages according to the Banff criteria.
Anti-ETAR (+) Anti-ETAR(−)
Acute rejection 8/55 (14.5%) 9/61 (14.8%)
IA, IB 3/55 (5.4%) 7/61 (11.5%)
IIA, IIB 4/55 (7.2%) 1/61 (1.6%)
AHR 1/55 (1.8%) 1/61 (1.6%)
IA, IB—cases with interstitial inﬁltration and tubulitis.
IIA, IIB—cases with arteritis.
AHR—acute humoral rejection.
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compared to the anti-ETAR(−) group during the ﬁrst post-transplant year (Fig. 1). One
month after transplantation serum creatinine in the anti-ETAR (+) patients (pts) was
1.86 ± 0.8 mg/dl and 1.51 ± 0.5 in the anti-ETAR(−) pts (p = 0.009). Twelve months
after transplantation the difference between the groups was still observed 1.70 ± 0.7 vs.
1.40 ± 0.4 (p = 0.04).
Biopsy proven acute rejectionwas recognized in 8/55 (14.5%) in the ETAR(+) and9/61
(14.8%) in the ETAR(−) patients (Table 3). Cases with mild to severe intimal arteritis
(v1–v3) were more often observed in patients with the presence of anti-ETAR Abs 4/55
(7.2%), comparing with 1/61 (1.6%) in the anti-ETAR(−) patients but did not achieve
statistical signiﬁcance. Acute humoral rejection was diagnosed in 1 case in each of the ob-
served groups. Four renal transplant recipients with Banff IIA or IIB acute rejection did not
develop anti-HLA antibodies veriﬁed by ﬂow cytometry during a one-year observation.
Arteritis and chronic vasculopathywere assessed according to anti-ETAR level (Table 6).
The incidence of vasculopathy or arteritis among patients with anti-ETAR ≥ 2.5 U/mL was
higher (p = 0.0275).
The mean level of anti-ETAR Abs in patients with acute rejection described as IIA and
IIB according to Banff classiﬁcation was 9.0 U/mL.
The association of chronic rejection risk factors with the presence of anti-ETAR was
checked by univariate andmultivariate logistic regression analyses (Table 4).We checked
inﬂuence of a recipient's age or gender, the duration of dialysis treatment, the number of
grafts, last or max PRA, the number of HLA mismatches or anti-HLA antibodies on the
presence of anti-ETAR. The association of creatinine (6th and 12th month) with the pres-
ence of anti-ETARwas checked by univariate logistic regression with signiﬁcant inﬂuence
(Table 5).
4. Discussion
Wehave demonstrated that renal transplant patients have preformed
non-HLA anti-ETAR antibodies and their presence has an inﬂuence on
renal transplant function during the ﬁrst year after transplantation.
Antibody mediated activity directed against a variety of non-HLA
antigens is established in renal transplant recipients. Identiﬁed non-
HLA targets include MICA [20,21], vimentin [22], angiotensin II type 1
receptor [12,23], tubulin [24], myosin [25], and collagen [26].
Vascular endothelium is thought to be a primary target of non-HLA
antibodies [9]. The endothelium has a crucial location between the
intravascular and interstitial compartment. It is responsible for the
hemodynamics regulation, angiogenic vascular remodeling but also
metabolic, synthetic and anti-inﬂammatory or antithrombogenicmech-
anisms [17]. Vascular abnormalities can be observed during acute but
also chronic renal allograft rejection [27,28]. They are associated with
glomerulopathy, ﬁbrointimal hyperplasia of arteries and arteriolar
hyalinosis. Such an injury is considered to be mainly an antibody-
mediated injury response to mismatched immunogenic epitopes afterTable 4
Risk factors for anti-ETAR.
Univariate analysis
OR 95% CI p
Male Recipient 1.9357 0.8957–4.1832 0
Recipient's age 0.9819 0.9576–1.0068 0
Duration of dialysis 0.9999 0.9995–1.0002 0
No. of grafts 0.9602 0.351–2.9258 0
Max PRA 1.0038 0.947–1.0338 0
No. of MM HLA ABDR 0.9121 0.6778–12273 0
anti-HLA Abs 0.8164 0.3294–.0234 0
OR—odds ratio, PRA—panel reactive antibodies, MM—mismatch, No.—number, HLA ABDR—humrenal transplantation. The role of donor speciﬁc anti-HLA antibodies in
renal transplant damage is known, while the signiﬁcance of non-HLA
antibodies remains anunresolved concern [29–31]. Non-HLA antibodies
both allo- or autoantibodies may also participate in the arterial wall
structural injury, which supports clothing and/or narrowing. For
instance, anti-angiotensin type 1 receptor (AT1R) antibodies may act
as an allosteric activator similar to natural ligand for the AT1R [23].
Antigenic targets for non-HLA antibodies can be produced in activated
or injured cells. Moreover, the cytokine mediated endothelial cell acti-
vation may also induce non-HLA response. Cytokine storm during
brain death and inﬂammation associated with an ischemia–reperfusion
injury can cause an increased expression of antigens and can stimulate
the non-HLA antibody creation [17,32].
Anti-ETAR antibodies may alone induce endothelial activation [19].
The basic function of endothelin receptor is to promote vasoconstric-
tion, growth and inﬂammation. Endothelins also support the growth
and proliferation of vascular smooth muscle cells. The effect appears
to be ETA receptor-mediated and involves not only the activation of
mitogen-activated protein kinases but also the transactivation of epi-
dermal growth factor receptor [33]. Endothelin receptors are pleiotropic
and possibly activate proinﬂammatory, proproliferative and proﬁbrotic
responses as well [19].
Dragun et al. reported the presence of similar non-HLA, agonistic
angiotensin type 1 receptor (AT1R) antibodies in 16 recipients of renal
allograft who had severe vascular rejection [23].
They described the AT1-receptor activity in steroid-refractory, C4d
negative renal allograft rejection in patients with hypertension. AT1-R
antibodies can induce phosphorylation of ERK 1/2 in the cells of endo-
thelium. The researchers indicate that binding AT1R Abs to the AT1
receptor is a critical step for the activation of the signaling cascade and
the induction of a renal graft damage.
Hiemann et al. prospectively tested the inﬂuence of anti-ETAR and
anti-AT1R antibodies in heart transplant recipients at the time of trans-
plantation and in the ﬁrst year after transplantation. They noticed that
elevated levels of anti-AT1R Abs and anti-ETAR Abs are connected
with cellular and humoral rejection and additionally with early onset
of microvasculopathy [14]. Hiemann et al. noticed a strong correlation
between anti-ETAR and anti-AT1R Abs levels at all time points moni-
tored after heart transplantation (r = 0.953; p b 0.001). Dragun et al.
discovered anti-AT1R antibodies which revealed arteritis and/or vascu-
lar necrosis in 16/33 renal recipients with vascular rejection in renal
transplantation [11,23,34]. Recently it has also been discussed that anti-
genic targets— twoG-protein coupled receptors: AT1 and ETA receptors
may have an important clinical signiﬁcance in transplantation [10]. To
our knowledge we are the ﬁrst who decided to check the inﬂuence of
anti-ETAR antibodies on renal function in consecutive recipients and an-
alyze the renal biopsy changes, especially in vessels. Knowingnumerous
studies of Dragun et al. and bearing in mind a high correlation of anti-
ETAR and anti-AT1R antibodies in Hiemann et al. study we decided to
examine the signiﬁcance of anti-ETAR antibodies without anti-AT1R
Abs. We supposed that endothelium antigens expressed on endothelial
cells play an important role in vessel injury leading to vasculopathy and
renal insufﬁciency.Multivariate analysis
Coefﬁcient Std. error p
.0930 1.6409 0.6667 0.0138
.1522 −0.0026077 0.023291 0.9109
.5065 −0.00026903 0.00025924 0.2994
.9431 0.32830 1.07488 0.7600
.8003 0.012329 0.025229 0.6251
.5433 −0.13636 0.27062 0.6144
.6614 0.36312 0.72378 0.6159
an leukocyte antigen A, B, DR, Abs—antibodies.
Table 5
The association of creatinine (6th and 12th month) with the presence of anti-ETAR
(univariate logistic regression).
Parameter Coefﬁcient Std. error p-Value
Anti-ETAR (creatinine 6th month) 0.3307 0.1055 0.0024
Anti-ETAR (creatinine 12th month) 0.2988 0.1296 0.0239
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renal transplant recipients in pre- and post-transplant screening. The
function of renal transplant function was signiﬁcantly worse in patients
with anti-ETAR activity comparing to anti-ETAR negative patients. We
have also noticed a more often delayed graft function in patients with
anti-ETAR Abs (25.4% vs.11.5%).
The presented data support the concept of non-HLA pathways
being an important trigger of transplant injury. Patients with anti-
ETAR activity may present vascular injury more frequently than
patients without anti-ETAR activity after heart transplantation [14].
Renal transplantologists should also consider endothelial activation
and dysfunction in the pathogenesis of renal allograft injury. Abs direct-
ed against endothelin-1 typeA receptor (ETAR)may alone induce endo-
thelial activation and damage of renal transplant. In our patients with
anti-ETAR Abs four of them developed changes characteristic of vascu-
lar damage with mild to severe arteritis (Banff IIA, IIB) previously
described as vascular rejection. It should be emphasized that more
cases of vasculopathy or arteritis were observed in patients with anti-
ETAR ≥ 2.5 U/mL (p = 0.0275).
Recently two interesting studies describing the non-HLA role after
renal transplantation have been published. Giral et al. noticed the
important role of pretransplant anti-AT1R Abs as an independent risk
factor for long-term graft loss in association with a higher risk of early
AR episodes [35]. The study included 599 kidney recipients whose
pretransplant sera were examined for the presence of anti-AT1R Abs
using a quantitative solid-phase assay. Taniguchi et al. tested anti-
AT1R Abs and DSA (anti-HLA) in pre- and posttransplant sera from
351 consecutive kidney recipients. Patients with both anti-AT1R and
DSA had lower graft survival than thosewithDSA alone [36]. The conﬁr-
mation that non-HLA antibodies are associated with graft injury is
increasing but the exact triggers for this response and the impact on
graft injury remain unclear [37]. Non-HLA Abs induced by transplant
have been described for all solid organ allografts with incidence ranges
from 10% to 100% of recipients [37]. An important issue of transplant
associated humoral immunity is how non-HLA antibodies participate
in the development of allograft vasculopathy. A stronger effect, acute
vascular rejection and malignant hypertension in renal transplantTable 6
The presence of arteritis or vasculopathy in renal biopsy in patients with anti-ETAR
antibodies.
Anti-ETAR antibodies level
b2.5 U/mL ≥2.5 U/mL
a) Arteritis
Cases with arteritis 1 4
Cases without arteritis 8 4
Signiﬁcance level p = 0.13
b) Chronic vasculopathy
Cases with chronic vasculopathy 1 6
Cases without chronic vasculopathy 8 2
Signiﬁcance level p = 0.015
c) Arteritis or chronic vasculopathy
Cases with arteritis or chronic vasculopathy 7 1
Cases without arteritis or chronic vasculopathy 2 7
Signiﬁcance level p = 0.0275recipients have been described with the presence of anti-AT1R antibod-
ies [23] but also in our observations. Vascular injury, mild to severe
intimal arteritis (v1–v3) were more often observed in the patients
with the presence of anti-ETAR Abs 4/55 (7.2%) comparing with 1/61
(1.6%) in the anti-ETAR(−) patients (Table 2). However, the incidence
of non-HLA antibody mediated acute vascular rejection may be critical
but not a major clinical problem after renal transplantation. Antibody
mediated non-HLA immunity due to its chronicity can have an impor-
tant impact on gradual progression of allograft vasculopathy and chron-
ic allograft injury [31,38,39].
Non-HLA antibodies which target vascular receptors (anti-AT1R Abs
and anti-ETARAbs) increase alloimmune activity andmicrovasculopathy
after transplantation of a heart (HTx) [14]. Patients after HTxwith elevat-
ed anti-AT1R (53%) or ETAR Abs (50%) developed microvasculopathy
more often (67% vs. 23%) comparing to patients without it [14]. These
observations allow putting forward a conclusion that elevated levels of
anti-AT1R and anti-ETAR Abs are associated with cellular and humoral
rejection and microvasculopathy and thus should be regularly moni-
tored after heart transplantation [14].
We realized that we were not able to indicate how high the level of
Abswhichmay surely trigger graft injury should be, butwe showed that
the 2.5 U/mL cut-off determined a worse graft function and more cases
of vasculopathyor arteritis.We analyzed the results repeatedly at differ-
ent times: before transplantation and then in 1st, 3rd, 6th, 12th month
after transplantation. If the result before was b2.5 U/mL, it was very
rarely observed higher in 1st, 3rd, 6th, 12thmonth after transplantation,
but if the result was ≥2.5 U/mL before transplantation it was suscepti-
ble to changes after transplantation and very often reached even more
than 10 U/mL. Such ﬁndings led to performing the analysis for different
levels andﬁnally resulted in noticing the biggest signiﬁcant difference in
transplant function (Fig. 1) but also more cases with vasculopathy or
arteritis (p = 0.0275) when the level of anti-ETAR was ≥2.5 U/mL.
The Spearman correlation test additionally conﬁrmed the signiﬁcant
difference in renal function.
The relationship between non-HLA antibodies and graft failure does
not automatically mean that antibody is responsible for graft injury. It
may specify nonpathogenic “spectator” activation that is triggered by
aggressive immune response. There are two elementary deliberations
whichdeterminewhether humoral immunity stimulates allograft rejec-
tion or not: expression of target antigens on graft and the possibility of
triggering injury during Abs ligation.
The mechanism of triggering vasculopathy can be considered as cell
lysis or endothelial cells activation [37]. Cultures with antiendothelial
antibodies may induce endothelial cell (EC) apoptosis [40]. It can be
stimulated in the absence of complement, which is suggested by direct
signal transduction but binding of antibody to ECmay also interact with
complement (C1q component) to activate the classical pathway. The
membrane attack complex (MAC) kills target EC through necrosis or ap-
optosis [37,41]. Another othermechanism for triggering vasculopathy is
through intracellular signaling cascades activating ECwhich can involve
tyrosine phosphorylation of focal adhesion kinase, upregulation of Rho
proteins and activation of Mammalian target of rapamycin pathways
[42–44]. Focal adhesion kinase and the Rho family proteins participate
in ﬁber formation and cytoskeletal organization, which might be the
explanation why binding of alloantibodies induces EC proliferation
[44,45]. Rho kinase inhibitor therapy blocked vasculopathy develop-
ment in a mouse after HTx model [46].
Hiemann et al. observed that a signiﬁcant proportion of patients with
elevated anti-AT1R Abs and anti-ETAR Abs developedmicrovasculopathy
in biopsy already in the ﬁrst year after HTx. Microvasculopathy is charac-
terized by a proliferation of vascular smooth muscle cells and vascular
remodeling of capillaries [47,48]. ETAR antibodies are expressed not
only on vascular cells but also in cardiomyocytes,ﬁbroblasts, and immune
cells [49]. Hiemann et al. even cautiously suggest that not only AT1R, but
also ETAR Abs can function not only as EC Abs but also part of high-risk
immunologic proﬁle capable of triggering an alloimmune response [14].
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cause earlier onset of microvascular remodeling [14]. The signiﬁcance
of ETAR Abs may be supported by research which shows that ETAR
antagonist LU 302146 (LU) not only abrogated chronic transplant
vasculopathy model in rats but also attenuated chronic transplant
nephropathy in the Fisher-to-Lewis rat model [50,51].
The collapse of B-cell self-tolerance seems to be crucial in under-
standing chronic rejection injury [10]. Presentation of antigens in
various cell stress conditions may induce an autoimmune response. In-
ﬂammatory events connected, among others, with ischemia or anti-HLA
activity may direct to de-novo expression of autoantigens and a loss of
tolerance [52]. Further research is required to conﬁrm our ﬁndings
and establish diagnostic or maybe even targeted therapies in the future.
Pharmacologic antagonists at the ETAR are applied in pulmonary arteri-
al hypertension treatment but also tested in other diseases. Plasmaphe-
resis or immunoadsorption are known and approved in the reduction of
antibodies titers [10].
Our analysis showed that the presence of anti-ETAR antibodies is
linkedwith aworse renal transplant function during theﬁrst 12 months
after transplantation and also revealed more cases with mild to severe
intimal arteritis in pts with anti-ETAR antibodies. Including anti-ETAR
antibodies in diagnostics of renal transplant recipient immune status
should be considered for comprehensive assessment of humoral
alloimmunity.
The study suggests monitoring of ETAR antibodies before and after
renal transplantation for the purpose of further assessment of immuno-
logic risk proﬁles and the identiﬁcation of patients highly susceptible to
immunologic events, glomerulopathy and graft loss.
In conclusion, anti-ETAR antibodies targeting vascular receptors
may be useful as novel biomarkers for the detection of renal transplant
recipients at risk of alloimmune activity. The detection and monitoring
of anti-ETAR antibodies might help in the overall immunological
assessment.References
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